Free Trial

Cytokinetics (CYTK) Stock Price, News & Analysis

Cytokinetics logo
$44.55 -2.02 (-4.34%)
Closing price 04:00 PM Eastern
Extended Trading
$45.42 +0.87 (+1.95%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytokinetics Stock (NASDAQ:CYTK)

Key Stats

Today's Range
$43.87
$46.07
50-Day Range
$41.56
$51.12
52-Week Range
$40.53
$75.71
Volume
1.31 million shs
Average Volume
1.48 million shs
Market Capitalization
$5.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.00
Consensus Rating
Moderate Buy

Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Remove Ads

Cytokinetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

CYTK MarketRank™: 

Cytokinetics scored higher than 87% of companies evaluated by MarketBeat, and ranked 142nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cytokinetics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cytokinetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytokinetics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytokinetics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cytokinetics' valuation and earnings.
  • Percentage of Shares Shorted

    12.19% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Cytokinetics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cytokinetics does not currently pay a dividend.

  • Dividend Growth

    Cytokinetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.19% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Cytokinetics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cytokinetics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Cytokinetics this week, compared to 9 articles on an average week.
  • Search Interest

    Only 1 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,949,275.00 in company stock.

  • Percentage Held by Insiders

    Only 3.40% of the stock of Cytokinetics is held by insiders.

  • Read more about Cytokinetics' insider trading history.
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
Cytokinetics announces launch of EARTH-HCM
See More Headlines

CYTK Stock Analysis - Frequently Asked Questions

Cytokinetics' stock was trading at $47.04 at the start of the year. Since then, CYTK stock has decreased by 5.3% and is now trading at $44.55.
View the best growth stocks for 2025 here
.

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. The biopharmaceutical company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million.

Cytokinetics' top institutional investors include Vanguard Group Inc. (10.10%), T. Rowe Price Investment Management Inc. (9.11%), Geode Capital Management LLC (2.41%) and Price T Rowe Associates Inc. MD (2.22%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, John T Henderson, Andrew Callos, Wendall Wierenga, B Lynne Parshall, Muna Bhanji, Robert Wong and Robert Arthur Harrington.
View institutional ownership trends
.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and General Electric (GE).

Company Calendar

Last Earnings
2/27/2025
Today
3/25/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTK
Employees
250
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$82.00
High Stock Price Target
$120.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+84.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-526,240,000.00
Net Margins
-17,906.25%
Pretax Margin
-17,906.25%

Debt

Sales & Book Value

Annual Sales
$18.47 million
Price / Cash Flow
N/A
Book Value
($3.94) per share
Price / Book
-11.31

Miscellaneous

Free Float
114,002,000
Market Cap
$5.28 billion
Optionable
Optionable
Beta
0.95

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CYTK) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners